LM11A 31Alternative Names: LM11A-31; LM11A-31-BHS
Latest Information Update: 29 Jul 2016
At a glance
- Originator PharmatrophiX
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 11 Jun 2016 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in Austria (PO) (EudraCT2015-005263-16)
- 19 May 2016 Chemical structure information added